Mounting evidence from recent studies has demonstrated the clinical efficacy of HDAC inhibitors across various neurological disorders, including Parkinson’s disease and Alzheimer’s disease, among others (Zhang et al., 2024). This evidence concerns the gene HDAC9 and Parkinson disease.